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Bbil-TX, a PLA2, was puri�ed from Bothriopsis bilineata snake venom aer only one chromatographic step using RP-HPLC on
𝜇𝜇-Bondapak C-18 column. A molecular mass of 14243.8Da was con�rmed by �-Tof �ltima API ESI/MS �T�� MS mode� mass
spectrometry.e partial protein sequence obtained was then submitted to BLASTp, with the search restricted to PLA2 from snakes
and shows high identity values when compared to other PLA2s. PLA2 activity was presented in the presence of a synthetic substrate
and showed aminimum sigmoidal behavior, reaching itsmaximal activity at pH 8.0 and 25–37∘C.MaximumPLA2 activity required
Ca2+ and in the presence of Cd2+, Zn2+, Mn2+, and Mg2+ it was reduced in the presence or absence of Ca2+. Crotapotin from
Crotalus durissus cascavella rattlesnake venom and antihemorrhagic factor DA2-II from Didelphis albiventris opossum sera under
optimal conditions signi�cantly inhibit the enzymatic activity. Bbil-TX induces myonecrosis in mice. e fraction does not show
a signi�cant cytotoxic activity in myotubes and myoblasts �C2C12�. e in�ammatory events induced in the serum of mice by
Bbil-TX isolated from Bothriopsis bilineata snake venom were investigated. An increase in vascular permeability and in the levels
of T��-a, IL-6, and IL-1 was was induced. Since Bbil-TX exerts a stronger proin�ammatory e�ect, the phospholipid hydrolysis
may be relevant for these phenomena.
1. Introduction
Viperidae snakes are represented in South America by Cro-
talus, Bothrops, Bothriopsis and Lachesis. Bothriopsis bilineata
is the endemic and rare bothropic snake species [1].
e envenomation is characterized by a generalized
in�ammatory state. e normal reaction to envenomation
involves a series of complex immunologic cascades that
ensures a prompt protective response to venom in humans
[2]. Although activation of the immune system during
envenomation is generally protective, septic shock develops
in a number of patients as a consequence of excessive or
poorly regulated immune response to the injured organism
[3]. is imbalanced reaction may harm the host through a
maladaptitive release of endogenous mediators that include
cytokines and nitric oxide.
PLA2s are abundant in snake venoms and have been
widely employed as pharmacological tools to investigate their
role in diverse pathophysiological processes. Viperid and
crotalid venoms contain PLA2s with the ability to cause
rapid necrosis of skeletal muscle �bers, thus being referred
to as myotoxic PLA2s [4]. Local in�ammation is a prominent
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characteristic of snakebite envenomations by viperid and
crotalid species [5].
Furthermore, PLA2 myotoxins are relevant tools for the
study of key general in�ammatory mechanisms. High levels
of secretory PLA2 (sPLA2) are detected in a number of
in�ammatory disorders in humans, such as bronchial asthma
[6], allergic rhinitis [7], septic shock [8], acute pancreatitis
[9], extensive burning [10], and autoimmune diseases [11].
In addition, increased expression and release of sPLA2 have
been found in rheumatoid arthritis, in�ammatory bowel
diseases, and atherosclerosis [12, 13]. Mechanisms involved
in the proin�ammatory action of sPLA2 are being actively
investigated, and most of this knowledge is based on studies
using puri�ed venom PLA2s.
is paper describes the isolation and biochemical and
pharmacological characterization of new PLA2s from Both-
riopsis bilineata venom, Bbil-TX, and also the study of its
various toxic activities, including myotoxicity, cytotoxicity,
and in�ammation.
2. Materials andMethods
2.1. Venom and Reagents. Bothriopsis bilineata venom was
donated by Dr. Corina Vera Gonzáles. All chemicals and
reagents used in this work were of analytical or sequencing
grade and purchased from Sigma-Aldrich Co. (St. Louis,MO,
USA).
2.2. Reversed-Phase HPLC (RP-HPLC). Five milligrams of
the whole venom from Bothriopsis bilineata was dissolved in
200 𝜇𝜇L ammonium bicarbonate 0.2M pH 8.0. e resulting
solution was clari�ed by centrifugation and the supernatant
was applied to a 𝜇𝜇-Bondapak C18 column (0.78 × 30 cm;
Waters 991—PDA system). Fractions were eluted using a
linear gradient (0–100%, v/v) of acetonitrile (solvent B) at
a constant �ow rate of 1.0mL/min over 40min. e elution
pro�le was monitored at 280 nm, and the collected fractions
were lyophilized and conserved at −20∘C.
2.3. PLA2 Activity. PLA2 activity was measured using the
assay described by Holzer and Mackessy, [14] modi�ed for
96-well plates. e standard assay mixture contained 200𝜇𝜇L
of buffer (10mM tris-HCl, 10mM CaCl2 and 100mMNaCl,
pH 8.0), 20 𝜇𝜇L of substrate (4-nitro-3-octanoyloxy-benzoic
acid), 20 𝜇𝜇L ofwater, and 20 𝜇𝜇L of Bbil-TX in a �nal volume of
260 𝜇𝜇L. Aer adding Bbil-TX (20 𝜇𝜇g), the mixture was incu-
bated for up to 40min at 37∘C,with the reading of absorbance
at intervals of 10min. e enzyme activity, expressed as the
initial velocity of the reaction (𝑉𝑉𝑜𝑜), was calculated based on
the increase of absorbance aer 20min. e optimum pH
and temperature of the PLA2 were determined by incubating
the enzyme in four buffers of different pH values (4–10)
and at different temperatures, respectively. e effect of
substrate concentration (0.1, 0.2, 0.3, 0.5, 1, 2, 5, 10, 20, and
30mM) on enzyme activity was determined by measuring
the increase of absorbance aer 20min. e inhibition of
PLA2 activity by crotapotins fromCrotalus durissus cascavella
and DAII-2 from Didephis albiventris serum was determined
by preincubating the protein (Bbil-TX) and each inhibitor
for 30min at 37∘C prior to assaying the residual enzyme
activity under optimal conditions. All assays were done in
triplicate and the absorbances at 425 nm were measured with
a VersaMax 190 multiwell plate reader (Molecular Devices,
Sunnyvale, CA, USA).
2.4. Electrophoresis. Tricine SDS-PAGE in a discontinuous
gel and buffer systemwas used to estimate themolecularmass
of the proteins, under reducing and nonreducing conditions
[15].
2.5. Amino Acid Analysis. Amino acid analysis was
performed on a Pico-Tag Analyzer (Waters Systems) as
described by [16]. e puri�ed Bbil-TX sample (30 𝜇𝜇g) was
hydrolyzed at 105∘C for 24 h in 6M HCl (Pierce sequencing
grade) containing 1% phenol (w/v). e hydrolyzates
were reacted with 20 𝜇𝜇L of derivatization solution (eth-
anol : triethylamine : water : phenylisothiocyanate, 7 : 1 : 1 : 1,
v/v) for 1 h at room temperature, aer which the PTC-amino
acids were identi�ed and quanti�ed by HPLC, by comparing
their retention times and peak areas with those from a
standard amino acid mixture.
2.�. Determination of the Molecular Mass of the Puri�ed
Protein by Mass Spectrometry. An aliquot (4.5 𝜇𝜇L) of the
protein was inject by C18 (100 𝜇𝜇m × 100mm) RP-UPLC
(nanoAcquity UPLC, Waters) coupled with nanoelectro-
spray tandem mass spectrometry on a Q-T of Ultima API
mass spectrometer (MicroMass/Waters) at a �ow rate of
600 nl/min. e gradient was 0–50% acetonitrile in 0.1%
formic acid over 45min. e instrument was operated in
MS continuummode and the data acquisition was from𝑚𝑚𝑚𝑚𝑚
100–3,000 at a scan rate of 1 s and an interscan delay of 0.1 s.
e spectra were accumulated over about 300 scans and the
multiple charged data produced by the mass spectrometer
on the 𝑚𝑚𝑚𝑚𝑚 scale were converted to the mass (molecular
weight) scale using maximum-entropy-based soware (1)
supplied with Masslynx 4.1 soware package.e processing
parameters were: output mass range 6,000–20,000Da at a
“resolution” of 0.1Da/channel; the simulated isotope pattern
model was used with the spectrum blur width parameter
set to 0.2Da and the minimum intensity ratios between
successive peaks were 20% (le and right). e deconvoluted
spectrumwas then smoothed (2 × 3 channels, Savitzky Golay
smooth) and the mass centroid values obtained using 80% of
the peak top and a minimum peak width at half height of 4
channels.
2.7. Analysis of Tryptic Digests. e protein was reduced
(DTT 5mM for 25min to 56∘C) and alkylated (Iodoac-
etamide 14mM for 30min) prior to the addition of trypsin
(Promega�s sequencing grade modi�ed). Aer trypsin addi-
tion (20 ng/𝜇𝜇L in ambic 0.05M), the sample was incubated
for 16 hr at 37∘C. To stop the reaction, formic acid 0.4% was
added and the sample centrifuged at 2500 rpm for 10min.
e pellet was discarded and the supernatant dried in a speed
vac. e resulting peptides were separated by C18 (100𝜇𝜇m ×
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100mm) RP-UPLC (nanoAcquity UPLC, Waters) coupled
with nanoelectrospray tandem mass spectrometry on a Q-
Tof Ultima API mass spectrometer (MicroMass/Waters) at
a �ow rate of 600 nl/min. Before performing a tandem
mass spectrum, an ESI/MS mass spectrum (TOF MS mode)
was acquired for each HPLC fraction over the mass range
of 100–2000𝑚𝑚𝑚𝑚𝑚, in order to select the ion of interest;
subsequently, these ions were fragmented in the collision cell
(TOF MS/MS mode).
Raw data �les from LC-MS/MS runs were processed
using Masslynx 4.1 soware package (Waters) and analyzed
using the MASCOT search engine version 2.3 (Matrix Sci-
ence Ltd.) against the snakes database, using the following
parameters: peptide mass tolerance of ±0.1Da, fragment
mass tolerance of ±0.1Da, and oxidation as variable modi-
�cations in methionine and trypsin as enzyme.
2.8. Myotoxic Activity. Groups of four Swiss mice (18–20 g)
received an intramuscular (i.m.) or an intravenous (i.v.)
injection of variable amounts of the Bbil-TX. Samples (50𝜇𝜇L)
containing 0.1, 1, and 5𝜇𝜇g of the PLA2 Bbil-TX were
injected in the right gastrocnemius. A control group received
50 𝜇𝜇L of PBS. At different intervals, blood was collected
from the tail into heparinized capillary tubes aer 2, 4,
6, 9, 12 and 24 hours, and the plasma creatine kinase
(CK; EC 2.7.3.2) activity was determined by a kinetic assay
Ck-Nac, (creatine kinase, Beacon, Diagnostics, Germany).
To the reaction mixture 10 𝜇𝜇L of the plasma obtained by
centrifugation from mice blood was added. e solution
is incubated for 2 minutes and reads at 430 nm. e
results were expressed as U/L according to the manufac-
turer.
2.9. Cytotoxicity Assays. Cytotoxic activity was assayed on
murine skeletal muscle C2C12 myoblasts and myotubes
(ATCC CRL-1772). Variable amounts of Bbil-TX were
diluted in assay medium (Dulbecco’s Modi�ed Eagle’s
Medium supplemented with 1% fetal-calf serum) and
added to cells in 96-well plates, in 150 𝜇𝜇L. Controls
for 0 and 100% toxicity consisted of assay medium,
and 0.1% Triton X-100, respectively. Aer 3 h at 37∘C,
a supernatant aliquot was collected for determination
of lactic dehydrogenase (LDH; EC 1.1.1.27) activity
released from damaged cells, using a kinetic assay
(Wiener LDH-P UV). Experiments were carried out in
triplicate.
2.10. Edema-Forming Activity. e ability of Bbil-TX to
induce edema was studied in groups of �ve Swiss mice
(18–20 g). Fiy microliters of phosphate-buffered saline
(PBS; 0.12M NaCl, 0.04M sodium phosphate, pH 7.2) with
Bbil-TX (0.1; 1 and 5 𝜇𝜇g/paw) were injected in the subplantar
region of the right footpad. e control group received an
equal volume of PBS alone. e paw swelling was measured
with an Electronic Caliper Series 1101 (INSIZE LTDA, SP,
Brazil) at 0.5, 1, 3, 6, 9, and 24 h aer administration. Edema
was expressed as the percentage increase in the size of the
treated group to that of the control group at each time equal
to 24 hrs.
2.11. Cytokines. e levels of cytokines IL-6 and IL-1 in
the serum from BALB/c mice were assayed by a two-
site sandwich enzyme-like immunosorbent assay (ELISA)
as described by [17]. In brief, ELISA plates were coated
with 100 𝜇𝜇L (1 𝜇𝜇g/mL) of the monoclonal antibodies anti-
IL-6 and anti-IL-1 placed in 0.1M sodium carbonate buffer
(pH 8.2), and incubated for 6 hours at room temperature.
e wells were then washed with 0.1% phosphate-buffered
saline (PBS/Tween 20) and blocked with 100 𝜇𝜇L of 10% fetal-
calf serum (FCS) in PBS for 2 hours at room temperature.
Aer washing, duplicate sera samples of 50 𝜇𝜇L were added
to each well. Aer 18 hours of incubation at 4∘C, the wells
were washed and incubated with 100 𝜇𝜇L (2 𝜇𝜇g/mL) of the
biotinylated monoclonal antibody anti-IL-6 and anti-IL-1 as
a second antibody for 45 minutes at room temperature. Aer
a �nal wash, the reaction was developed by the addition of
orthophenyldiamine (OPD) to each well. Optical densities
weremeasured at 405 nm in amicroplate reader.e cytokine
content of each sample was read from a standard curve estab-
lishedwith the appropriate recombinant cytokines (expressed
in picograms per millilitre). e minimum levels of each
cytokine detectable in the conditions of the assays were
10 pg/mL for IL-6 and IL-1.
To measure the cytotoxicity of TNF-𝛼𝛼 present in the
serum from BALB/c mice, a standard assay with L-929
cells, a �broblast continuous cell line, was used as described
previously by [18].epercentage cytotoxicity was calculated
as follows: (Acontrol − Asample𝑚Acontrol)× 100. Titres were
calculated as the reciprocal of the dilution of the sample in
which 50% of the cells in the monolayer were lysed. TNF-𝛼𝛼
activity is expressed as units/mL, estimated from the ratio of
a 50% cytotoxic dose of the test to that of the standard mouse
recombinant TNF-𝛼𝛼.
2.12. Statistical Analysis. Results are reported as means ±
SEM. e signi�cance of differences between the means was
assessed by ANOVA followed by Dunnett’s test when various
experimental groups were compared with the control group.
A value of 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 indicated signi�cance.
3. Results
Fractionation of Bothriopsis bilineata venom by RP-HPLC on
a 𝜇𝜇-Bondapak C18 column resulted in eleven peaks (1–11)
(Figure 1). e 11 peaks were screened for myotoxic and
PLA2 activities. Peak 7 caused localmyotoxicity at concentra-
tions ranging from 0.1 to 5 𝜇𝜇g/mL in mouse gastrocnemius
muscle. In addition, peak 7, named Bbil-TX-I (Bothriopsis
bilineata toxin) showed high PLA2 activity and was selected
for biochemical and pharmacological characterization. e
purity of this peakwas con�rmed by rechromatography on an
analytical RP-HPLC 𝜇𝜇-Bondapack C18 column, showing the
presence of only one peak and by Tricine SDS-PAGE, which
revealed the presence of one electrophoretic band with Mr
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F 2: Mass determinations of Bbil-TX by mass spectrometry,
using a Q-Tof Ultima API ESI/MS (TOF MS mode).
around 15 kDa, in the absence and presence of DTT (1M)
(data not shown).
Q-Tof Ultima API ESI/MS (TOF MS mode) mass
spectrometry analysis con�rmed the homogeneity of the
peak Bbil-TX and determined the exact molecular mass of
14243.8Da (Figure 2).is value of molecular mass was used
in calculating the molar concentrations of toxin used in the
experiments described below.
e alkylated and reduced protein was digested with
trypsin and the resulting tryptic peptides (10) were frac-
tionated by RP-UPLC (nanoAcquity UPLC, Waters) (data
not shown). Before performing a tandem mass spectrum, an
ESI/MS mass spectrum (TOF MS mode) was acquired for
each HPLC fraction over the mass range of 100–2000𝑚𝑚𝑚𝑚𝑚,
in order to select the ion of interest; subsequently, these
ions were fragmented in the collision cell (TOF MS/MS
mode). e data �les obtained from LC-MS/MS runs were
processed using the Masslynx 4.1 soware package (Waters)
and analyzed using the MASCOT search engine version
2.3 (http://www.matrixscience.com/). Table 1 shows the
deduced sequence andmeasuredmasses of alkylated peptides
obtained for Bbil-TX PLA2. Isoleucine and leucine residues
were not discriminated in any of the sequences reported
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1504.5356. Ion of the major sequence-speci�c 𝑦𝑦-ion series and of a
minor series of the complementing b-ions CCFVHDCCYGK, from
which the sequence of Bbil-TX tag was deduced.
since they were indistinguishable in low energy CID spectra.
Because of the external calibration applied to all spectra,
it was also not possible to resolve the 0.041Da difference
between glutamine and lysine residues, except for the lysine
that was deduced based on the cleavage and missed cleavage
of the enzyme.
e ten peptides obtained in Q-Tof Ultima API ESI/MS
(TOF MS mode) mass spectrometry of the Bbil-TX PLA2
were submitted to the NCBI database, using the protein
search program BLASTp with the search being restricted to
the sequenced proteins from the basic protein with phospho-
lipase A2 activity family. Based on the positional matches
of the de novo sequenced peptides with other homologous
proteins, it was possible to deduce the original positions of
these peptides in the native protein (Figure 4).
e results of the primary structures show that Bbil-TX
PLA2 is composed of 122 amino acid residues and shares
the conserved sequence domains common to PLA2 group,
including the 14 cysteines, the calcium-binding site located
on (Y)27, (G)28, (C)31, and (G)32, and the catalytic network
commonly formed by (H)48, (D)49, (Y)52, and (D)90. A
comparative analysis of the sequence of Bbil-TX PLA2 with
other neurotoxins “ex vivo” and myotoxic PLA2s belonging
to Viperidae family, LmTX-I and LmTX-II (Lachesis muta
muta) [19] and Crotalus scutulatus scutulatus (Mojave rat-
tlesnake) (accession number P62023), showed similarity of
81.1–91.0%. (SwissProt database http://br.expasy.org/). e
tandem mass spectra shown in Figure 3, relative to the
peptide eluted in fraction 3 having the sequence C C F V H
D C C Y G K, allows to classify both enzymes as PLA2.
Amino acid analysis revealed the following composition
of Bbil-TX PLA2: D/11, T/7, S/2, E/12, P/9, G/10, A/7,
C/14, V/4, M/2, I/3, L/7, Y/9, F/4, K/12, H/1, and R/6.
e PLA2 activity was examined in the Bothopsis bilineata
venom and in BbilTX-I using the synthetic substrate 4-
nitro-3(octanoyloxy) benzoic acid [14, 19].e PLA2 activity
was higher in Bbil-TX (24.75 ± 2.68 nmols/min/mg) when
compared with the whole venom (8.15±1.24 nmols/min/mg)
(Figure 5(a)). Under the conditions used, Bbil-TX showed a
discrete sigmoidal behavior (Figure 5(f)), mainly at low sub-
strate concentrations. Maximum enzyme activity occurred
at 35–40∘C (Figure 5(c)) and the pH optimum was 8.0
(Figure 5(d)). PLA2s require Ca+2 for full activity, with only
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T 1: Sequence obtained by MS/MS based on the alkylated tryptic peptides derived. e peptides were separated and sequenced by mass
spectrometry.
Residue number Mass (Da) expected Amino acid sequence Mass (Da) calculated
1–7 898.5293 HLLQFNK 898.5025
16–33 2157.9352 NAIPFYAFYGCYCGWGGR 2157.9189
43–53 1504.5356 CCFVHDCCYGK 1504.5356
61–69 1183.6216 WDIYPYSLK 1183.5913
70–77 884.4277 SGYITCGK 884.4062
78–90 871.8404 GTWCEEQICECDR 1741.6494
91–98 973.5307 VAAECLRR 973.5127
98–104 853.4780 RSLSTYK 853.4657
105–114 1297.5059 YGYMFYPDSR 1297.5437
115–122 965.3514 CRGPSETC 965.3695
Bbil TX
P0C942 1
P0C8M 1
P62023
Bbil TX
P0C942 1
P0C8M1 1
P62023
Bbil TX
P0c942 1
P0C8M 1
P62023
10 20
30 40 50 60
70 80 90
−D49
Ca2+ binding loop
-wingCatalitic site
F 4: Alignment of the deduced amino acid sequence of the new PLA2 Bbil-TX with PLA2 presents in venom of Lachesis muta muta
(accession number P0C8M_1 and P0C942_1) [19] and Crotalus scutulatus scutulatus (Mojave rattlesnake) (accession number P62023).
Nondetermined amino acid residues are indicated by (X); boxed amino acid residues are identical. e highlighted amino acid residues
belong to PLA2 conserved domain Ca2+-binding loop, the catalytic site, and the region 𝛽𝛽-wing.
1mM of Ca+2 needed for Bbil-TX to present phospholipase
activity. e addition of Mg2+, Cd2+, and Mn2+ (10mM) in
the presence of low Ca2+ concentration (1mM) decreases the
enzyme activity.e substitution of Ca2+ byMg2+, Cd2+, and
Mn2+ also reduced the activity to levels similar to those in the
absence of Ca2+ (Figure 5(e)).
e crotapotins are pharmacologically inactive and non-
enzymatic acid protein, binds speci�cally of the PLA2 inhib-
ited the activity. An isoform ofCrotalus durissus cascavella F3
and antihaemorragic factor DA2-II from Didelphis albiven-
tris, signi�cantly inhibit the Bbil-TX PLA2 activity (Figure
5(b)).
e local myotoxic effect (i.m.) in vivo was observed
with PLA2 Bbil-TX studied. It was observed that the PLA2
induced a conspicuous effect evidenced by the rapid elevation
of plasma CK activity through a time course, reaching its
maximum effect 2 h aer injection and returning to normal
levels aer 24 h (Figure 6(a)). Our results showed that the
PLA2Bbil-TX did not show systemic myotoxic effect (i.v.)
(Figure 6(b)).
In a concentration of 5, 10, 20, and 40𝜇𝜇g/well (150𝜇𝜇L),
the PLA2 Bbil-TX showed low cytotoxicity in skeletal muscle
myoblasts and myotubes (25.49 ± 2.3% and 29.05 ± 3.45%,
resp.) in a concentration of 40mg/well (150 𝜇𝜇L) (Figure 6(c)).
Compared to PBS-injected animals, those which received
subplantar injections of the Bbil-TX (0.1, 1, and 5 𝜇𝜇g/paw)
presentedmarked paw edema (Figure 7(a)). Maximal activity
was attained 1 h to the Bbil-TX aer injection and receded to
normal levels aer 24 h.e level of edema induction by 5𝜇𝜇g
of PLA2 1 hour aer administration was 61.57%, showing a
dose-dependent activity. To further analyze the mechanisms
of the in�ammatory events induced by Bbil-TX (0.1𝜇𝜇g),
TNF-𝛼𝛼, IL-6, and IL-1 concentrations were measured in the
serum. TNF-𝛼𝛼 levels were increased 1 h aer injection of Bil-
TX and no detectable production was observed at the later
time intervals studied (Figures 7(b), 7(c), and 7(d)). Bbil-
TX caused a signi�cant increase in IL-6 release between 1
and 3 h, respectively, in serum collected aer injection of
venom compared with the control (Figure 7(c)). However,
increased levels of IL-1 were detected between 1, 3, 6, and
12 h, respectively (Figure 7(d)).
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F 5: (a) PLA2 activity ofBothriopsis bilineata venom and peak 7 (Bbil-TX); (b) the inhibitory effect of the antihemorrhagic factor DAII-2
and the crotapotin F3 on PLA2 activity Bbil-TX; (c) effect of temperature on the PLA2 activity of Bbil-TX; (d) effect of pH on Bbil-TX activity;
(e) in�uence of ions (1�mM each) on PLA2 activity in the absence or presence of 1mM Ca2+; (f) effect of substrate concentration on the
kinetics of BbilTX (PLA2) activity. e inset shows the curve shape at low substrate concentrations. e results of all experiments are the
mean ± SE, of three determinations (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃).
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F 6: (a, b) Time course of the increments in plasma CK activity aer intramuscular (i.m.) or intravenous (i.v.) injection of 0.1, 1, and
5 𝜇𝜇g Bothriopsis bilineata Bbil-TX; (c) in vitro cytotoxic activity of Bbil-TX on murine C2C12 skeletal-muscle myoblasts and myotubes. Cell
lysis was estimated by the release of lactic dehydrogenase (LDH) to supernatants, aer 3 h of exposure to the toxins. Each point represents
mean ± SD of triplicate cell cultures.
4. Discussion
e puri�cation procedure for basic PLA2s developed by
[20–22] showed to be also efficient for the obtainment of
neurtoxin “ex vivo” and myotoxin from Bothriopsis bilin-
eata snake venom. Fractionation of this crude venom by
single-step chromatography in a column 𝜇𝜇-Bondapack C-
18 coupled to a system of reversed-phase HPLC was carried
out and as a result of the proposed method, several toxins
have been efficiently puri�ed. Fraction 7 was named Bbil-TX
(PLA2). SDS-PAGE showed evidence that Bbil-TX isolated
PLA2s have an Mr of ∼14 kDa for the monomers, similar to
basic PLA2s isolated from other venoms (data not shown)
[23]. e conserved residues Y28, G30, G32, D49, H48, and
Y52 are directly or indirectly linked in the catalyses of the
Bbil-TX.
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speci�c ELISA, and TNF-𝛼𝛼 was �uanti�ed by cytotoxic activity on L�2� cells in serum collected at the indicated time intervals aer Bbil-TX
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e molecular masses obtained by mass spectrometry
showed to be similar to that of other snake venom PLA2s
[22, 24, 25].e amino acid composition of the Bbil-TXPLA2
toxin suggests the presence of 14 half-Cys residues, providing
the basis for a common structural feature of PLA2 in the
formation of its seven disul�de bridges [20, 21, 26] and a
high content of basic and hydrophobic residues, that provides
a explication important in the interaction of the PLA2 with
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negatively charged phospholipids of cells membranes [27].
Such an interaction is important to explain the effect of
these enzymes on different cells types, both prokariotes and
eukariotes [28, 29].
Comparison of the amino acid sequence of Bbil-
TX PLA2 showed high homology with other neurotoxic
and myotoxic PLA2s from Lachesis and Crotalus genera
(Figure 4). Sequence homology studies had shown that
there are extremely conserved positions in the PLA2s. In
positions 1 and 2, there is a predominance of the amino
acid sequence (HL), in position 4 (Q), and in positions
5 to 7 (FNK). One of the highly conserved regions in
the amino acid sequences of PLA2 is the Ca2+-binding
loop, segment from…YGCYCGXGG… andHD(49)CC.e
calcium ion is coordinated by threemain chain oxygen atoms
from residues (Y)28, (G)30, (G)32, and two carboxylate
oxygen atoms of (D)49. Two generally conserved solvent
water molecules complete the coordination sphere of the
calcium ion forming a pentagonal bipyramidal geometry.
It is believed that two disul�de bridges (C)27–(C)119 and
(C)29–(C)45 ensure the correct relative orientation of the
calcium-binding loop in relation to the amino acids of the
catalytic network [30]. e residues (H)48, (Y)52, and (D)99
which are responsible for catalytic activity have an ideal
stereochemistry with the presence of the so-called “catalytic
network”, a system of hydrogen bonds which involves the
catalytic triad [30, 31]. Residues forming the Ca2+-binding
loop and the catalytic network of Bbil-TX PLA2 show a high
conservation grade, re�ecting the nondecreased catalytic
activity.
e PLA2 activity was shown to be higher in Bbil-
TX PLA2 (24.75 ± 2.28 nmoles/min/mg) when compared
with the whole venom (8.15 ± 1.24 nmoles/min/mg). PLA2
enzyme from snake venom shows classic Michaelis–Menten
behavior against micellar substrates [32]. With a synthetic
substrate, Bbil-TX PLA2 behaved allosterically, especially at
low concentrations, which is in agreement with the results
obtained by [23] for the PLA2 of Bothrops jararacussu
venom and Damico et al. [19] for the PLA2 isoform puri�ed
from Lachesis muta muta venom. Using the same synthetic
nonmicellar substrate, it was also possible to observe that
the dependence of activity on substrate concentration was
markedly sigmoidal for the PrTX-III from Bothrops pirajai
[33].
PLA2s from crotalic venoms have showed a similar
behavior to the one presented by bothropic PLA2s with the
same substrate used in the kinetic studies to Bbil-TX PLA2
[14, 34]. Despite the structural and functional differences
among bothropic and crotalic PLA2s, both show allosteric
behavior in the presence of the same substrate.
e PLA2 activity could be veri�ed with different pH
levels; the optimum pH of basic PLA2s is around 7.0 and
8.5 [32, 35]. Bbil-TX PLA2 can be considered basic since
its highest activity is evidenced at pH 8.0. Temperature is
another kinetic parameter utilized to characterize the PLA2
(Asp49). It has been shown that PLA2 from Naja naja naja is
very stable in extreme temperatures such as 100∘C [35]. e
optimum temperature of Bbil-TX PLA2 was around 37∘C, but
at 40–45∘C, the Bbil-TX PLA2 activity did not present a huge
decrease.
A strict requirement for Ca2+ is characteristic of some
PLA2 [5]. Bbil-TX PLA2 showed typical Ca2+-dependent
PLA2 activity similar to other PLA2s, and this activity was
lower in the presence of other cations. [14, 35–38] observed
the same for other PLA2 from snake venom.
e crotapotin isoform fromCrotalus durrissus cascavella
(F3) venom inhibit signi�cantly the PLA2 activity of Bbil-
TX by approximately 50%. Our results are in agreement
with the �nding by [14, 21, 39] who reported that highly
puri�ed crotapotin can inhibit pancreatic, bee, and other
snake venomPLA2s, andBon�met al. [23], who reported that
crotapotins from Crotalus durissus terri�cus (F7), Crotalus
durissus collilineatus (F3 and F4), and Crotalus durissus
cascavella (F3 and F4) decreased the catalytic activity of BJ
IV (PLA2 from Bothrops jararacussu) by 50%. Together, these
results suggest that crotapotinmay bind to bothropic PLA2 in
a manner similar to that from crotalic PLA2.
Bbil-TX PLA2 increases the plasmatic CK levels aer
i.m. injection (Figure 6(a)), revealing drastic local myotox-
icity. is myotoxicity induced by snake venoms, including
Botrhiopsis bilineata, may result from the direct action of
myotoxins on the plasma membranes of muscle cells, or
indirectly, as a consequence of vessel degenerations and
ischemia caused by hemorrhagins or metaloproteases. Bbil-
X PLA2 contributes signi�cantly to local myotoxic action
in vivo. It was already demonstrated that the snake venom
PLA2s are the principal cause of local damage [40]. Myotoxic
PLA2s affect directly the plasma membrane integrity of
muscle cells, originating an in�ux of Ca2+ ions to the citosol
that starts several degenerative events with irreversible cell
injures [41]. e binding sites of myotoxins on the plasma
membranes are not clearly established, although two types
have been proposed: (a) negatively charged phospholipids
[42], present on membranes of several cell types, explaining
the high in vitro cytotoxic action of these enzymes [28, 43, 44],
and (b) protein receptors, which make muscle cells more
susceptible to myotoxin action [28].
All these biological effects induced by the toxin occur in
the presence of a measurable PLA2 activity. Although the
catalytic activity of PLA2s contributes to pharmacological
effects, it is not a prerequisite [21, 26, 29]. However, further
studies are necessary to identify the structural determinants
involved in these pharmacological activities.
Some authors, [21, 41, 45, 46], have proposed several
models to explain PLA2 catalytic and pharmacological activ-
ities. In these models PLA2 has two separated places; one is
responsible for catalytic activity and the other for biological
activity expression. According to them, the pharmacological
place would be located on the surface of PLA2 molecules.
According to the model proposed by [47], the anti-coagulant
place would be located in a region between the 53 and 76
residues, considering this region charged positively in the
PLA2 with high anticoagulant activity. In PLA2 with mod-
erate or low anticoagulant activity, there is a predominancy
of negative charges.
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Further research in identifying target proteins will help
determine details of the mechanisms of the pharmacological
effects at the cellular and molecular levels [48]. Studies
in these areas will result in new, exciting, and innovative
opportunities and avenues in the future, both in �nding
answers to the toxicity of PLA2 enzymes and in developing
proteins with novel functions.
PLA2s from snake venoms exert a large number of
pharmacological activities due to a process of accelerated
evolution through which a highmutational rate in the coding
regions of their genes has allowed the development of new
functions, mainly associated with the exposed regions of the
molecules [29]. e integral analysis of the in�ammation
elicited by Bbil-TX in the mouse serum performed in the
present study allowed a parallel evaluation of the increase
in microvascular permeability and the production of various
in�ammatory mediators. Bbil-TX induced an increase in
vascular permeability in the paw ofmice.is is in agreement
with previous observations on the edema-forming activity
of similar molecules in the rodent footpad model [49,
50].
e increase of vascular permeability was detected early
aer Bbil-TX injection and developed rapidly, indicating
that the observed plasma extravasation is primarily due to
formation of endothelial gaps in vessels of microcirculation.
emain edema formation occurred 1 h aer the injection of
Bbil-TX with constant decrease. Bbil-TX caused paw edema
in mice with a time course similar to that reported for other
PLA2s from Bothrops venoms inmice and rats, that is, a fairly
rapid onset (generally ≤ 3 h to peak) followed by a gradual
decline over the following 24 h [51–54].
emediators involved in this effect of Bbil-TXmyotoxin
were not addressed in this study. However, the immediate
plasma extravasation in response to Bbil-TX strongly sug-
gests the involvement of vasoactive mediators derived from
mast-cell granules. is strongly suggests that enzymatic
phospholipid hydrolysis plays a signi�cant role in this event.
Cytokines, such as IL-1, IL-6, and TNF-𝛼𝛼, are also
relevant mediators for leukocyte migration and participate
in several in�ammatory conditions. �ur results showed that
Bbil-TX induced an increase in TNF-𝛼𝛼, IL-6, and IL-1 in the
serum [55].us, our results suggest that IL-1may contribute
to the leukocyte in�ux induced by Bbil-TX. In addition,
the similarity observed in the time course of IL-6 and IL-
1 increase in the serum may indicate a positive regulatory
role for IL-1 on the release of IL-6 induced by Bbil-TX. IL-6,
an important mediator of in�ammation, causes leukocytosis
characterized by a rapid neutrophilia by releasing of PMN
leukocytes from the bone marrow [56, 57]. In addition, IL-
6 upregulates intercellular-adhesion-molecule-1 (ICAM-1)
expression by endothelial cells but decreases the levels of L-
selectin on circulating PMN leukocytes contributing to �rm
adhesion, the next step of cell migration [58].
TNF-𝛼𝛼 is also likely to be involved in leukocyte in�ltra-
tion induced by Bbil-TX, since the PLA2 caused a signi�cant
increase of TNF-𝛼𝛼 levels in the serum. TNF-𝛼𝛼 is likely
to induce the expression of E-selectin, CD11b/CD18, and
intercellular adhesion molecule-1 (ICAM-1) and triggers
the release of several cytokines such as IL-1 and IL-6 and
eicosanoids. us, our results suggest that TNF-𝛼𝛼 may have
a role in the expression of CD18 and the release of other
cytokines following Bbil-TX injection, thereby being relevant
for neutrophil in�ux and for increase of vascular permeabil-
ity. It is interesting that TNF-𝛼𝛼 and IL-6, as well as IL-1, may
induce or potentiate the expression and release of group IIA
PLA2s [59, 60].
In conclusion, Bbil-TX induces a marked in�amma-
tory reaction in the mouse serum. Since basic myotoxic
PLA2s are abundant in snake venoms, these toxins must
play a relevant role in the proin�ammatory activity that
characterizes this venom. e fact that Bbil-TX elicited a
stronger in�ammatory reaction argues in favor of a role
of enzymatic phospholipid hydrolysis in this phenomenon,
either through the direct release of arachidonic acid from
plasma membranes or through activation of intracellular
processes in target cells.
Accumulating evidences have strongly shown that venom
PLA2s are among the major mediators of myonecrosis [40],
hemolysis, mast cell degranulation, and edema formation [3].
PLA2s isolated from Bothrops venoms are frequently
myotoxic [26] and can cause edema in rats and mice [39, 45,
49, 54]. ese results suggest that, for some PLA2s, catalytic
activity plays a role in the edematogenic effect.
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